Animal models of sepsis (Q85716911)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24022070%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

3 December 2020

Animal models of sepsis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24022070%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

3 December 2020

1 reference

3 December 2020

Mitchell P Fink

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24022070%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

19 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24022070%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 January 2014

1 reference

3 December 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24022070%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

3 December 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24022070%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24022070%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

143-153

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24022070%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 3.0 Unported

20 February 2020

copyright license

1 reference

The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis

3 December 2020

cites work

1 reference

12 December 2020

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 reference

12 December 2020

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

1 reference

12 December 2020

Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study

1 reference

12 December 2020

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

1 reference

12 December 2020

Characterization of a hyperdynamic murine model of resuscitated sepsis using echocardiography

1 reference

12 December 2020

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

1 reference

12 December 2020

Animal models of sepsis

1 reference

12 December 2020

Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

1 reference

12 December 2020

A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction.

1 reference

12 December 2020

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock

1 reference

12 December 2020

Pretreatment with troglitazone decreases lethality during endotoxemia in mice.

1 reference

12 December 2020

LPS-induced cytokine production in human monocytes and macrophages

1 reference

12 December 2020

Drotrecogin alfa (activated) in adults with septic shock.

1 reference

12 December 2020

Scavenger receptor class a plays a central role in mediating mortality and the development of the pro-inflammatory phenotype in polymicrobial sepsis

1 reference

12 December 2020

Preclinical sepsis models

1 reference

12 December 2020

A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis

1 reference

12 December 2020

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group

1 reference

12 December 2020

Influence of hypercortisolemia on soluble tumor necrosis factor receptor II and interleukin-1 receptor antagonist responses to endotoxin in human beings

1 reference

12 December 2020

CDP571, a humanized antibody to human tumor necrosis factor-alpha

1 reference

12 December 2020

Interleukin 10 reduces mortality from severe peritonitis in mice

1 reference

12 December 2020

Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation

1 reference

12 December 2020

A critical role of leukotriene B4 in neutrophil migration to infectious focus in cecal ligaton and puncture sepsis

1 reference

12 December 2020

Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis

1 reference

12 December 2020

Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis

1 reference

12 December 2020

Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial

1 reference

12 December 2020

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

1 reference

12 December 2020

Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice

1 reference

12 December 2020

Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, p

1 reference

12 December 2020

Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock

1 reference

12 December 2020

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial

1 reference

12 December 2020

Antibiotics delay but do not prevent bacteremia and lung injury in murine sepsis.

1 reference

12 December 2020

Genetic factors in leucocyte responses to endotoxin: further studies in mice.

1 reference

12 December 2020

Significant contribution of spleen cells in mediating the lethal effects of endotoxin in vivo

1 reference

12 December 2020

BCG-induced enhancement of endotoxin sensitivity in C3H/HeJ mice. I. In vivo studies

1 reference

12 December 2020

Effectiveness of steroid/antibiotic treatment in primates administered LD100 Escherichia coli

1 reference

12 December 2020

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli

1 reference

12 December 2020

Species differences in Kupffer cells and endotoxin sensitivity.

1 reference

12 December 2020

The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study

1 reference

12 December 2020

A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock

1 reference

12 December 2020

Cardiopulmonary responses to continuous administration of endotoxin

1 reference

12 December 2020

Relationships between tumour necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice

1 reference

12 December 2020

Laboratory models of sepsis and septic shock

1 reference

12 December 2020

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

12 December 2020

A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice

1 reference

12 December 2020

A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group

1 reference

12 December 2020

Anti-endotoxin monoclonal antibodies

1 reference

12 December 2020

Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia

1 reference

12 December 2020

Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration

1 reference

12 December 2020

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 reference

12 December 2020

Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081.

1 reference

12 December 2020

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

1 reference

12 December 2020

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

1 reference

12 December 2020

Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock

1 reference

12 December 2020

Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomized phase II trial

1 reference

12 December 2020

Endogenous modulators of TNF and IL-1 response are under partial control of TNF in baboon bacteremia.

1 reference

12 December 2020

Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group

1 reference

12 December 2020

The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group

1 reference

12 December 2020

Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis

1 reference

12 December 2020

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators

1 reference

12 December 2020

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group

1 reference

12 December 2020

Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group

1 reference

12 December 2020

p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group

1 reference

12 December 2020

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

1 reference

12 December 2020

Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Animal models of sepsis and shock: a review and lessons learned.

1 reference

12 December 2020

Animal models of sepsis and its complications

1 reference

12 December 2020

Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting?

1 reference

12 December 2020

Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)

1 reference

12 December 2020

Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice

1 reference

12 December 2020

Hemopexin down-regulates LPS-induced proinflammatory cytokines from macrophages

1 reference

12 December 2020

Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model

1 reference

12 December 2020

Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.

1 reference

12 December 2020

Animal models of sepsis and sepsis-induced kidney injury

1 reference

12 December 2020

Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial

1 reference

12 December 2020

Animal models of sepsis

1 reference

12 December 2020

Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis

1 reference

12 December 2020

Resilience to bacterial infection: difference between species could be due to proteins in serum

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis

1 reference

12 December 2020

Lipid A receptor TLR4-mediated signaling pathways

1 reference

12 December 2020

Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial.

1 reference

12 December 2020

Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial

1 reference

12 December 2020

Genomic responses in mouse models poorly mimic human inflammatory diseases

1 reference

12 December 2020

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial

1 reference

12 December 2020

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation.

1 reference

12 December 2020

Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia

1 reference

12 December 2020

An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan.

1 reference

12 December 2020

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group

1 reference

12 December 2020

Protective effects of anti-O polysaccharide and anti-lipid A monoclonal antibodies on pulmonary hemodynamics.

1 reference

12 December 2020

A controlled trial of HA-1A in a canine model of gram-negative septic shock.

1 reference

12 December 2020

Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin.

1 reference

12 December 2020

Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock

1 reference

12 December 2020

Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation

1 reference

12 December 2020

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

1 reference

12 December 2020

Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5.

1 reference

12 December 2020

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group

1 reference

12 December 2020

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

1 reference

12 December 2020

Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.

1 reference

12 December 2020

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

1 reference

12 December 2020

Use of antithrombin III in critical patients

1 reference

12 December 2020

Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis.

1 reference

12 December 2020

Reversal of late septic shock with supraphysiologic doses of hydrocortisone

1 reference

12 December 2020

Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.

1 reference

12 December 2020

Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis

1 reference

12 December 2020

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group

1 reference

12 December 2020

Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group

1 reference

12 December 2020

Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product

1 reference

12 December 2020

Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study

1 reference

12 December 2020

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

1 reference

12 December 2020

Anti-inflammatory response is associated with mortality and severity of infection in sepsis.

1 reference

12 December 2020

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

1 reference

12 December 2020

Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock

1 reference

12 December 2020

Rodent models of intra-abdominal infection

1 reference

12 December 2020

Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial.

1 reference

12 December 2020

Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis

1 reference

12 December 2020

Safety and efficacy of affinity-purified, anti–tumor necrosis factor-α, ovine fab for injection (CytoFab) in severe sepsis*

1 reference

12 December 2020

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

1 reference

12 December 2020

Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model.

1 reference

12 December 2020

Hydrocortisone therapy for patients with septic shock

1 reference

12 December 2020

Noradrenaline and nomega-monomethyl-L-arginine (L-NMMA): effects on haemodynamics and regional blood flow in healthy and septic sheep

1 reference

12 December 2020

A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.

1 reference

12 December 2020

Identifiers

DOI

10.4161/VIRU.26083

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24022070%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24022070%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference